Is Aklief in shortage in 2026? Get the latest update on Aklief availability, why it's hard to find, current pricing, and what patients can do right now.
If you've been trying to fill your Aklief (Trifarotene) prescription and running into empty shelves and long wait times, you're probably wondering: is Aklief in shortage? The answer is more nuanced than a simple yes or no.
In this update, we'll cover the current availability situation, explain why Aklief is hard to find in 2026, break down the latest pricing, and give you practical steps to get your medication.
As of March 2026, Aklief is not listed on the FDA Drug Shortage Database. This means there isn't an official, manufacturer-reported supply disruption for Trifarotene cream.
However, that doesn't tell the whole story. Many patients report difficulty finding Aklief at their local pharmacies. This is what we call an access shortage — the drug exists and is being manufactured, but getting it into patients' hands is complicated by cost barriers, insurance restrictions, and inconsistent pharmacy stocking.
Think of it this way: the supply chain is working, but the access chain is broken for many people.
Several factors combine to create access difficulties:
Aklief has no generic equivalent. Trifarotene is only available as the brand-name product from Galderma. Without generics to increase supply and lower prices, the market is limited to a single manufacturer and a single price point.
The cash price for a 45g pump of Aklief ranges from $760 to $1,080 depending on the pharmacy. This price discourages pharmacies from stocking large quantities and discourages patients from filling without insurance coverage.
While roughly 80% of commercial plans include Aklief in their formulary, prior authorization is almost always required. Many insurers also mandate step therapy — meaning you have to try and fail on cheaper retinoids like Tretinoin or Adapalene before they'll cover Aklief. These processes create delays that can last days or weeks.
Only about one-third of ACA marketplace plans cover Aklief at all. Medicaid coverage varies by state and is often limited.
Because of low turnover (driven by cost and insurance hurdles), many pharmacies — particularly large chains — don't keep Aklief in regular inventory. They'll order it when a prescription comes in, but that adds 1–3 days to your wait.
For a deeper look at why this happens, read: Why Is Aklief So Hard to Find?
Here's a breakdown of current Aklief pricing:
The Galderma CareConnect savings card is by far the best deal for eligible patients. However, it's not available for government-insured patients (Medicare, Medicaid, Tricare, VA). For complete savings information, see: How to Save Money on Aklief.
While no generic Trifarotene is on the immediate horizon, there are a few developments worth watching:
Here's your action plan:
For step-by-step guidance, read: How to Find Aklief in Stock Near You.
Aklief isn't in a traditional shortage — there's no manufacturing or supply chain crisis. But for many patients, the combination of high cost, no generic option, and insurance barriers makes it feel like a shortage. The drug is available, but accessing it requires navigating a system that doesn't always make it easy.
The key is to be proactive: use tools like Medfinder, take advantage of savings programs, and work closely with your dermatologist. If Aklief truly isn't accessible, there are effective alternatives worth discussing with your provider.
Check availability now: Find Aklief in stock on Medfinder.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
